149104-92-7

Basic information

• Product Name: 4-BROMO-3-METHYLBENZYLAMINE
• Synonyms: 4-BROMO-3-METHYLBENZYLAMINE;BenzeneMethanaMine, 4-broMo-3-Methyl-;4-BroMo-3-MethylbenzylaMine HCl
• CAS NO: 149104-92-7
• Molecular Formula: C₈H₁₀BrN
• Molecular Weight: 200.078
• Product Categories: Anilines, Aromatic Amines and Nitro Compounds
• Mol File: 149104-92-7.mol

Chemical Properties

• Boiling Point: 266.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.410±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.92±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3-METHYLBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-METHYLBENZYLAMINE(149104-92-7)
• EPA Substance Registry System: 4-BROMO-3-METHYLBENZYLAMINE(149104-92-7)

Safety Data

• Hazardous Substances Data: 149104-92-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-METHYLBENZYLAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving existing ones. Its role in the creation of active pharmaceutical ingredients (APIs) is vital for advancing medical treatments.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-3-METHYLBENZYLAMINE is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its involvement in the synthesis of these compounds helps to enhance crop protection and increase agricultural productivity.
Used in Organic Synthesis:
4-BROMO-3-METHYLBENZYLAMINE is employed as a reagent in organic chemical reactions, facilitating the formation of new organic compounds with potential applications in various industries, including materials science, fragrances, and dyes.
Used in Research and Development:
As a valuable building block, 4-BROMO-3-METHYLBENZYLAMINE is also used in research and development for exploring new chemical pathways, discovering novel compounds, and understanding the fundamental principles of organic chemistry. Its versatility makes it an essential tool for scientific inquiry and innovation.

Upstream product

• 170229-98-8 4-Bromo-3-methylbenzenecarboxamidamide 
• 41963-20-6 4-bromo-3-methylbenzonirtile 
• 6933-10-4 amino-5-bromo-2-toluene 

Downstream Products

• 1008736-37-5 4-aminomethyl-2-methyl-benzonitrile 
• 1220039-91-7 tert-butyl N-[(4-bromo-3-methylphenyl)methyl]carbamate 

Relevant articles and documents

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1 was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar Ki achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy.